BGLC vs SYF · rev $99.0K vs rev $11.19B
BioNexus Gene Lab Corp Common stock (BGLC) versus SYF (SYF) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
SYF (SYF) common stock.
Latest reported BGLC revenue for 2026-06-30 was $99.0K. Net income was -$830.0K. BGLC currently screens at market cap $6.1M.
Latest reported SYF revenue for 2026-06-30 was $11.19B. Net income was $1.69B. Revenue was up 99.6% from 2026-03-31 to 2026-06-30. SYF currently screens at market cap $0.
BGLC currently screens at market cap $6.1M. SYF currently screens at market cap $0.
Not investment advice. Open the BGLC and SYF stock pages for the full models.
Not investment advice.